Chronic Pancreatitis Pipeline: Clinical Trials, Emerging Therapies and Key pharma players involved by DelveInsight

July 28 13:20 2021
Chronic Pancreatitis Pipeline: Clinical Trials, Emerging Therapies and Key pharma players involved by DelveInsight

Chronic Pancreatitis Pipeline

Chronic pancreatitisis commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance. Chronic pancreatitis is usually a complication of recurrent episodes of acute pancreatitis.

 

DelveInsight’s, “Chronic Pancreatitis Pipeline Insight, 2021” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Chronic Pancreatitis Companies are:

  • CalciMedica
  • GNT Pharma
  • Koligo Therapeutics
  • Kangen Pharmaceuticals
  • AzurRx SAS
  • Theraly Fibrosis
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/chronic-pancreatitis-pipeline-insight

 

DelveInsight’s Chronic Pancreatitis report covers around 6+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Chronic Pancreatitis Therapies are:

  • Oral CRAC inhibitor
  • Flusalazine
  • KT CP 203
  • NI-03
  • MS1819-SD
  • TLY012
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/chronic-pancreatitis-pipeline-insight

 

Current Chronic Pancreatitis Treatment Scenario and Chronic Pancreatitis Emerging Therapies:

  • How many companies are developing Chronic Pancreatitis drugs?
  • How many Chronic Pancreatitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pancreatitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Pancreatitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Pancreatitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

 

Table of Contents:

Introduction

Executive Summary

Chronic Pancreatitis: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Chronic Pancreatitis – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Drug name: Company name

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

MS1819-SD: AzurRx SAS

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Flusalazine: GNT Pharma

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

• Comparative Analysis

Oral CRAC inhibitor: CalciMedica

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Chronic Pancreatitis Key Companies

Chronic Pancreatitis Key Products

Chronic Pancreatitis- Unmet Needs

Chronic Pancreatitis- Market Drivers and Barriers

Chronic Pancreatitis- Future Perspectives and Conclusion

Chronic Pancreatitis Analyst Views

Chronic Pancreatitis Key Companies

Appendix

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/lag-3-next-generation-immunotherapy-competitive-landscape